ICIEM 2021 Symposium: Rare neurometabolic disorders: A focus on aromatic L-amino acid decarboxylase (AADC) deficiency
View the PTC Therapeutics symposium at ICIEM 2021, which reviews clinical and real-life experiences of AADC deficiency and provides an overview of current and potential future management options
Understand the etiology and clinical features of AADC deficiency, and how this differs from other neurotransmitter disorders
Learn from clinical cases that illustrate real-life presentation, key signs and symptoms, and steps to diagnosis
Management approaches for the treatment of AADC deficiency are outlined
Learn about the clinical trial experience of an investigational gene replacement therapy for the treatment of AADC deficiency
This symposium was developed and funded by PTC Therapeutics at ICIEM 2021. It was not part of the official program of ICIEM 2021.
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2200021 | March 2022
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.